BIOGEN INC. Severance Costs
BIOGEN INC. (BIIB) reported Severance Costs of $7.10 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-04-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2023-04-25
- BIOGEN INC. severance costs for the quarter ending 2023-03-31 was $7.10M, a 74.37% decline year-over-year.
- BIOGEN INC. severance costs for the quarter ending 2022-12-31 was $2.40M.
- BIOGEN INC. severance costs for the quarter ending 2022-09-30 was $21.60M.
- BIOGEN INC. severance costs for the quarter ending 2022-06-30 was $60.90M.
- BIOGEN INC. severance costs for fiscal 2022 was $112.60M.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2023-03-31 | $7.10M 10-Q · filed 2023-04-25 | $9.50M derived: sum of 2 quarters · filed 2023-04-25 | $31.10M derived: sum of 3 quarters · filed 2023-04-25 | $92.00M derived: sum of 4 quarters · filed 2023-04-25 |
| 2022-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $24.00M derived: sum of 2 quarters · filed 2023-02-15 | $84.90M derived: sum of 3 quarters · filed 2023-02-15 | $112.60M 10-K · filed 2023-02-15 |
| 2022-09-30 | $21.60M 10-Q · filed 2022-10-25 | $82.50M derived: sum of 2 quarters · filed 2022-10-25 | $110.20M 10-Q · filed 2022-10-25 | |
| 2022-06-30 | $60.90M 10-Q · filed 2022-07-20 | $88.60M 10-Q · filed 2022-07-20 | ||
| 2022-03-31 | $27.70M 10-Q · filed 2023-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |